STK11 Antibody

What is STK11/LKB1 and why is it important in cancer research?

STK11 (Serine/Threonine Kinase 11), also known as LKB1, is a critical tumor suppressor protein that functions as a serine/threonine kinase. It controls the activity of AMP-activated protein kinase (AMPK) family members, playing vital roles in cell metabolism, polarity, apoptosis, and DNA damage response . STK11 is frequently inactivated in non-small cell lung cancer (NSCLC), particularly in tumors harboring KRAS mutations . Its status has emerged as a biomarker for predicting response to immunotherapies, as STK11-deficient tumors often show resistance to anti-PD-1 therapy .

Which applications are most commonly validated for STK11/LKB1 antibodies?

STK11/LKB1 antibodies have been extensively validated for several research applications:

How should I optimize Western blot protocols for STK11/LKB1 detection?

For optimal Western blot detection of STK11/LKB1:

• Use reducing conditions and appropriate immunoblot buffer (e.g., Immunoblot Buffer Group 1)

• Prepare PVDF membranes for optimal protein transfer

• Apply antibody at recommended dilutions (typically 0.5-2 μg/mL for monoclonal and 1:500-1:10000 for polyclonal antibodies)

• Expect to detect STK11/LKB1 at approximately 50-55 kDa

• Include appropriate controls, especially GAPDH as a loading control (critical for quantification)

• For validation, consider using STK11/LKB1 knockout cell lines (e.g., STK11 knockout HEK293T) as negative controls to confirm antibody specificity

How can I functionally assess STK11 variants identified in clinical samples?

Functional assessment of STK11 variants requires multiple complementary approaches:

• In vitro kinase assays: Assess autophosphorylation capacity of the STK11 variant using gel-shift assays. Wild-type STK11 typically shows two bands (unmodified and phosphorylated) while loss-of-function variants show only a single unmodified band

• Luciferase reporter assays: Measure STK11 variant effects on TP53's transcriptional activity using a p53-dependent luciferase reporter system

• STK11 heterotrimeric complex assessment: Transfect STK11 variants into STK11-deficient cells (e.g., A549), immunoprecipitate the complex, and perform kinase assays followed by Western blot analysis

• Splice-site variant analysis: For splice-site variants, sequence the tumor mRNA to definitively determine the molecular impact, as DNA sequence alone is insufficient

• Comparison with in silico prediction algorithms: Evaluate experimental results against computational predictions from multiple algorithms to assess concordance

What considerations are important when using STK11 antibodies for IHC in clinical samples?

For successful IHC applications with STK11 antibodies in clinical tissues:

• Epitope retrieval optimization: Use heat-induced epitope retrieval with appropriate buffer (recommended: Antigen Retrieval Reagent-Basic or TE buffer pH 9.0; alternative: citrate buffer pH 6.0)

• Protocol conditions: Incubate primary antibodies at optimal concentrations (1-10 μg/mL for monoclonal; 1:50-1:1200 for polyclonal) overnight at 4°C

• Detection system selection: For DAB staining, use appropriate HRP-conjugated secondary antibodies and visualization kits

• Subcellular localization interpretation: STK11/LKB1 can localize to both cytoplasm and nuclei, with specific staining patterns varying by tissue type and disease state

• Counterstaining: Use hematoxylin (blue) for contrast with the brown DAB staining to clearly visualize cellular structures

• Controls: Include known positive and negative controls, particularly STK11-deficient tissues or cell lines, to validate staining specificity

What are the experimental challenges in studying the relationship between STK11 mutations and immunotherapy response?

Researchers face several methodological challenges when investigating STK11 mutations and immunotherapy response:

• Variant classification complexity: Distinguishing between function-altering and benign STK11 variants requires rigorous functional assessment, particularly for missense mutations

• Tumor microenvironment effects: STK11/LKB1 deficiency promotes neutrophil recruitment with T-cell-suppressive effects, requiring complex immune profiling beyond simple PD-L1 expression analysis

• Cytokine analysis: STK11/LKB1-deficient tumors show altered cytokine profiles, including increased IL-6, necessitating comprehensive cytokine profiling

• Confounding genetic alterations: Co-occurring mutations, particularly KRAS mutations, must be accounted for in experimental design

• Therapeutic response assessment: STK11-mutated tumors show reduced response to PD-1 inhibitors but may respond to alternative approaches like IL-6-neutralizing antibodies or neutrophil-depleting antibodies

How do I validate the specificity of STK11/LKB1 antibodies?

Validate STK11/LKB1 antibody specificity through:

• Knockout validation: Use STK11/LKB1 knockout cell lines (e.g., LKB1/STK11 knockout HEK293T) as negative controls in Western blots

• Molecular weight verification: Confirm detection at the expected molecular weight (50-55 kDa for full-length STK11/LKB1)

• Multiple antibody comparison: Use antibodies targeting different epitopes of STK11/LKB1 to confirm consistent results

• Phosphatase treatment: For studies investigating phosphorylation, include phosphatase-treated samples to confirm band shifts are due to phosphorylation

• Recombinant protein controls: Use purified recombinant STK11/LKB1 as a positive control

• Cross-reactivity assessment: Test the antibody against closely related kinases to ensure specificity

What are best practices for storing and handling STK11/LKB1 antibodies to maintain activity?

To maintain optimal STK11/LKB1 antibody activity:

• Storage temperature: Store at -20°C to -70°C for long-term storage (stable for one year from receipt)

• Short-term storage: For reconstituted antibodies, store at 2-8°C under sterile conditions for up to one month

• Freeze-thaw cycles: Avoid repeated freeze-thaw cycles by aliquoting antibodies before freezing

• Reconstitution method: Reconstitute lyophilized antibodies at 0.5 mg/mL in sterile PBS

• Working dilution preparation: Prepare working dilutions fresh on the day of experiment

• Shipping conditions: Upon receipt of antibodies shipped at ambient temperature (lyophilized) or with polar packs (liquid), immediately store at recommended temperature

What controls are essential when studying STK11/LKB1 function in different experimental systems?

Essential controls for STK11/LKB1 functional studies include:

• Positive controls: Include cell lines known to express STK11/LKB1 (MCF-7, HepG2, K562)

• Negative controls: Use STK11/LKB1-deficient cell lines (e.g., A549) or knockout models

• Loading controls: For Western blots, always include GAPDH or other housekeeping proteins as loading controls

• Functional validation: For kinase activity studies, include wild-type STK11/LKB1 as a positive control and kinase-dead mutants as negative controls

• Phosphorylation controls: Use phosphatase treatment to confirm phosphorylation-dependent band shifts

• Isotype controls: For immunostaining experiments, include appropriate isotype control antibodies

How should I design experiments to investigate STK11's role in cancer immunotherapy resistance?

To investigate STK11's role in immunotherapy resistance:

• Cell line selection: Use isogenic cell line pairs (STK11 wild-type and STK11-deficient) preferably in KRAS-mutant backgrounds to model clinical scenarios

• In vivo models: Employ KRAS-driven NSCLC mouse models with and without STK11/LKB1 inactivation

• Immune profiling: Characterize tumor-infiltrating lymphocytes, neutrophil accumulation, and expression of T-cell exhaustion markers

• Cytokine analysis: Measure production of tumor-promoting cytokines, particularly IL-6, in the tumor microenvironment

• Therapeutic interventions: Test PD-1-targeting antibodies, IL-6-neutralizing antibodies, and neutrophil-depleting antibodies to compare response rates

• PD-L1 expression analysis: Evaluate PD-L1 expression levels as STK11/LKB1-inactivating mutations are associated with reduced PD-L1 expression

What experimental approaches can distinguish between wild-type and functionally impaired STK11 variants?

To distinguish functional from impaired STK11 variants:

• Gel-shift assays: Detect autophosphorylation capability through the presence of a higher molecular weight phosphorylated band, which is absent in non-functional variants

• TP53 transcriptional activity: Measure p53-dependent luciferase reporter activity as a readout of STK11 function

• AMPK phosphorylation assessment: Quantify phosphorylation of AMPK, a direct downstream target of STK11

• Subcellular localization studies: Examine nuclear versus cytoplasmic distribution of STK11 variants using immunofluorescence

• Protein stability analysis: Evaluate protein half-life through cycloheximide chase experiments to detect destabilizing variants

• Heterotrimeric complex formation: Assess the ability of STK11 variants to form functional complexes with STRAD and MO25 through co-immunoprecipitation

How can STK11 antibodies be utilized in patient stratification for clinical trials?

STK11 antibodies can contribute to patient stratification in clinical trials through:

• Tissue analysis: Perform IHC to evaluate STK11/LKB1 protein expression levels and subcellular localization in patient biopsies

• Correlation with genomic data: Compare IHC results with sequencing data to identify patients with STK11 mutations that result in protein loss versus those with preserved protein despite mutations

• Functional assessment: Classify patient STK11 variants as functional or non-functional through functional assays to guide enrollment in trials like those investigating TNG260 (CoREST inhibitor) combined with pembrolizumab in STK11-mutated solid tumors

• Biomarker development: Develop IHC-based screening protocols that can rapidly identify patients with STK11 loss in clinical settings

• Assay validation: Establish validated cut-off values for STK11 expression levels that correlate with clinical outcomes or drug response

• Combination biomarkers: Integrate STK11 status with other biomarkers (PD-L1 expression, tumor mutational burden) for more refined patient stratification

How should researchers interpret discrepancies between in silico predictions and experimental results for STK11 variant function?

When facing discrepancies between computational predictions and experimental data:

• Prioritize experimental evidence: Functional data from kinase assays and reporter systems should take precedence over in silico predictions

• Consider structural context: Evaluate the variant's location within functional domains or at interaction surfaces that might not be fully captured by prediction algorithms

• Assess algorithm limitations: Recognize that current prediction algorithms may not adequately account for STK11-specific functional mechanisms

• Compare multiple algorithms: Evaluate predictions from multiple computational tools (22+ algorithms are available) to identify consensus or outliers

• Refine model training: Use discrepant cases to improve algorithm training sets, particularly for kinase-specific prediction models

• Explore novel mechanisms: Consider that variants might affect function through mechanisms not captured by standard assays (e.g., protein-protein interactions, localization)

What methods can correlate STK11 expression patterns with clinical outcomes in cancer studies?

To correlate STK11 expression with clinical outcomes: